Foveal changes in aquaporin‐4 antibody seropositive neuromyelitis optica spectrum disorder are independent of optic neuritis and not overtly progressive
Adriana Roca‐Fernández(Hammersmith Hospital), Jacqueline Palace(John Radcliffe Hospital), Klemens Ruprecht(Charité - Universitätsmedizin Berlin), Alexander U. Brandt(Eli Lilly (United States)), Judith Bellmann–Strobl(Humboldt-Universität zu Berlin), Friedemann Paul(Max Delbrück Center), Seyedamirhosein Motamedi(Humboldt-Universität zu Berlin), Fay Probert(University of Oxford), Tianrong Yeo(Nanyang Technological University), Hanna Zimmermann(Humboldt-Universität zu Berlin), Joseph Kuchling(Max Delbrück Center), Frederike Cosima Oertel(Humboldt-Universität zu Berlin), Maria Isabel Leite(Mayo Clinic), Susanna Asseyer(Humboldt-Universität zu Berlin), Matthew Craner(University of Oxford), Jaume Sastre‐Garriga(Universitat Autònoma de Barcelona)
Cited by 17
Related Papers
MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines
|The Lancet Neurology|2016|863
MOG encephalomyelitis: international recommendations on diagnosis and antibody testing
|Journal of Neuroinflammation|2018|740
Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial
|The Lancet|2019|722
2021 MAGNIMS–CMSC–NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis
|The Lancet Neurology|2021|646